FOAMIX PHARMACEUTICALS LTD.
Foamix Pharmaceuticals is a specialty pharmaceutical company, committed to addressing unmet needs of patients by bringing innovative solutions to the field of dermatology. The company is in late-stage clinical development of two lead products based on the company’s first-in-class topical Minocycline Foam: FMX101, for the treatment of moderate-to-severe acne, and FMX102, for the treatment of impetigo. Having completed Phase II clinical trials of these product candidates, the company expects to initiate Phase III pivotal clinical trials for both in 2015 and file for subsequent U.S. regulatory approvals in 2016.
The Company collaborates with leading global pharmaceutical companies in the creation of advanced products with improved convenience, higher compliance and better efficacy, which are backed by an extensive patent portfolio. Our most advanced Rx product is currently in Phase III clinical trials.